Collagen Proteostasis in Heath and Disease

健康和疾病中的胶原蛋白稳态

基本信息

批准号：
10928439
负责人：
Matthew Donald Shoulders
金额：
$ 22.56万
依托单位：
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-19 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10928439
关键词：
Address Affect Animals Attention Basement membrane Biochemical Biochemistry Biological Models Cartilage Cells Chemicals Chronic stress Clinical Collagen Collagen Diseases Cystic Fibrosis Data Defect Deposition Disease Endoplasmic Reticulum Extracellular Matrix Face Failure Fibrillar Collagen Foundations Functional disorder Genes Genetic Genetic Diseases Health Human Human body In Vitro Intervention Knowledge Lead Lectin Life Missense Mutation Modality Modeling Modification Molecular Molecular Chaperones Mutation Nature Other Genetics Palliative Care Pathologic Pathway interactions Phenotype Physiological Play Polysaccharides Preclinical Testing Process Procollagen Production Property Proteins Quality Control Rapid screening Research Skin Structure Symptoms System Tendon structure Testing Therapeutic Tissue Model Tissues Work autosome bone effective therapy expectation fundamental research in vivo malformation novel therapeutic intervention pharmacologic pre-clinical protein aggregation protein misfolding proteostasis regenerative therapy scaffold screening small molecule targeted treatment triple helix

项目摘要

Collagen is the most abundant protein in animals, constituting up to one-third of total protein in humans. As the major proteinaceous component of tissues ranging from bone and skin to cartilage and basement mem- branes, it constitutes the molecular scaffold for animal life. This ubiquitous protein is challenging for cells to produce, requiring highly coordinated intracellular processes of folding, assembly, and quality control. Owing to the hierarchical nature of collagenous extracellular matrices, the physical and biochemical properties of these tissues are fundamentally defined by these upstream, intracellular processes. Defects, whether genetic or oth- erwise, that are detrimental to any aspect of collagen proteostasis can impact cell health or function and propa- gate to extracellular matrices, leading to diseases known as the collagenopathies. Unfortunately, these dis- eases almost universally lack effective, disease-modifying therapies. Current therapeutic strategies for the collagenopathies focus on regenerative therapies, efforts to strengthen the extracellular matrix itself, or palliative care. None of these approaches aim to address the up- stream issue leading to disease: a failure to properly fold and quality control collagen molecules themselves. If the breakdown of collagen proteostasis could be effectively addressed, the downstream symptoms targeted by current clinical strategies would be alleviated. Indeed, proteostasis enhancement has proven remarkably effi- cacious in many other genetic disorders, including cystic fibrosis, but it has yet to make serious inroads in the collagenopathies. One obstacle is inadequate understanding of the critical decision points in the collagen pro- teostasis network. Another issue is the challenge of pre-clinical testing of proteostasis-targeted interventions in a disease that requires robust, yet biochemically amenable, tissue model systems for discovery efforts. This R01 proposal seeks to address these knowledge gaps, both identifying and elucidating key mech- anisms of intracellular folding and quality control and assessing the therapeutic potential of proteostasis net- work-targeted therapeutics in the collagenopathies. In Aim 1, the functions of the highly conserved procollagen N-glycan in promoting folding, enabling quality control, and identifying when folded procollagens are ready for secretion will be elucidated, via comprehensive work both in cells and in vivo that will reveal the molecular mechanisms of collagen glycoproteostasis. The expectation is demonstration that the long-ignored procollagen N-glycan is actually the critical fulcrum of collagen proteostasis. In Aim 2, a state-of-the-art cartilage-in-a-dish model system is deployed to enable robust testing of proteostasis network-targeted therapies for the colla- genopathies. Combined with mechanistic studies to elucidate the biochemistry of dysregulated collagen prote- ostasis, work in this Aim will provide a strong foundation for a new, proteostasis-focused perspective on treat- ing the collagenopathies.

胶原蛋白是动物体内最丰富的蛋白质，占人类总蛋白质的三分之一。作为从骨骼和皮肤到软骨和基底膜等组织的主要蛋白质成分膜，它构成了动物生命的分子支架。这种无处不在的蛋白质对细胞来说具有挑战性生产，需要高度协调的折叠、组装和质量控制的细胞内过程。由于胶原细胞外基质的分级性质，这些物质的物理和生化特性组织从根本上是由这些上游的细胞内过程定义的。缺陷，无论是遗传的还是其他的反之，对胶原蛋白稳态的任何方面都不利的可能会影响细胞健康或功能以及传播通往细胞外基质的大门，导致称为胶原病的疾病。不幸的是，这些缓解几乎普遍缺乏有效的、缓解疾病的疗法。目前胶原蛋白病的治疗策略侧重于再生疗法，努力强化细胞外基质本身，或姑息治疗。这些方法都不是旨在解决上行问题导致疾病的流问题：胶原蛋白分子本身无法正确折叠和质量控制。如果胶原蛋白稳态的破坏可以得到有效解决，下游症状可以通过目前的临床策略将得到缓解。事实上，蛋白质稳态增强已被证明非常有效它对许多其他遗传性疾病（包括囊性纤维化）有严重影响，但尚未在疾病领域取得重大进展。胶原病。一个障碍是对胶原蛋白亲和力的关键决策点了解不够。睾丸稳态网络。另一个问题是针对蛋白质稳态的干预措施的临床前测试的挑战这种疾病需要强大且生化上可接受的组织模型系统来进行发现工作。该 R01 提案旨在解决这些知识差距，识别和阐明关键机制细胞内折叠和质量控制的本质以及评估蛋白质稳态网络的治疗潜力胶原病的以工作为目标的治疗方法。在目标 1 中，高度保守的前胶原蛋白的功能 N-聚糖促进折叠、实现质量控制以及识别折叠前胶原何时准备好通过细胞和体内的全面工作，将阐明分泌，这将揭示分子胶原糖蛋白稳态的机制。人们的期望是证明长期被忽视的前胶原蛋白 N-聚糖实际上是胶原蛋白稳态的关键支点。在目标 2 中，最先进的培养皿软骨部署模型系统是为了能够对胶原蛋白稳态网络靶向疗法进行可靠的测试基因病。结合机制研究阐明失调的胶原蛋白的生物化学稳态，这一目标的工作将为新的、以蛋白质稳态为重点的治疗观点提供坚实的基础。荷兰国际集团胶原蛋白病。